Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Take, for example, AlphaFold, the AI ...
NMR spectroscopy uncovers drug-target interactions, offering detailed insights into binding mechanisms and molecular dynamics ...
The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high potency, selectivity, and favorable metabolic properties—at the earliest stages ...
In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...
Five competing pharmaceutical companies have jointly trained a state-of-the-art AI model on more than 20,000 of their most closely guarded drug-discovery structures — without any company ever seeing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results